Part 11: The Impact of COVID-19 on Oncology Research: Immediate and Long-term Effects

June 10, 2020

More clinical trials are conducted for cancer than for other therapeutic areas, and these trials often include participants who have exhausted the available treatment options. So when COVID-19 forced a re-assessment of ongoing and upcoming studies, patients and care providers were placed in a difficult situation. We’ll talk to a leading cancer researcher and a patient who was in screening for a new clinical trial, about the present and future of oncology clinical trials.

Our expert speakers discuss:

  • How did cancer research centers react to COVID-19 and make decisions about continuing or pausing clinical trials, and what are they planning for the near future?
  • What kind of long-term effects might we see in the design and conduct of oncology clinical trials as a result of COVID-19?
  • The patient perspective: How it feels to get the call that your cancer clinical trial has been put on indefinite hold
Previous Flipbook
Part 12: Public Awareness of Clinical Research and the Path to Diversity in Clinical Trials
Part 12: Public Awareness of Clinical Research and the Path to Diversity in Clinical Trials

Next Flipbook
Part 10: Unique Challenges and Opportunities for Emerging Biopharma Companies with Focused Pipelines
Part 10: Unique Challenges and Opportunities for Emerging Biopharma Companies with Focused Pipelines